- Home
- AGEN vs SFWL Comparison
AGEN vs SFWL Comparison
Compare AGEN & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- SFWL
- Stock Information
- Founded
- AGEN 1994
- SFWL 2001
- Country
- AGEN United States
- SFWL China
- Employees
- AGEN N/A
- SFWL N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SFWL Trucking Freight/Courier Services
- Sector
- AGEN Health Care
- SFWL Industrials
- Exchange
- AGEN Nasdaq
- SFWL Nasdaq
- Market Cap
- AGEN 87.7M
- SFWL 81.0M
- IPO Year
- AGEN 2000
- SFWL 2023
- Fundamental
- Price
- AGEN $4.70
- SFWL $1.01
- Analyst Decision
- AGEN Buy
- SFWL
- Analyst Count
- AGEN 4
- SFWL 0
- Target Price
- AGEN $13.00
- SFWL N/A
- AVG Volume (30 Days)
- AGEN 1.7M
- SFWL 9.4K
- Earning Date
- AGEN 08-07-2025
- SFWL 07-07-2025
- Dividend Yield
- AGEN N/A
- SFWL N/A
- EPS Growth
- AGEN N/A
- SFWL 4.79
- EPS
- AGEN N/A
- SFWL 0.13
- Revenue
- AGEN $99,524,000.00
- SFWL $504,158,000.00
- Revenue This Year
- AGEN $12.69
- SFWL N/A
- Revenue Next Year
- AGEN N/A
- SFWL N/A
- P/E Ratio
- AGEN N/A
- SFWL $7.35
- Revenue Growth
- AGEN N/A
- SFWL 24.75
- 52 Week Low
- AGEN $1.38
- SFWL $0.86
- 52 Week High
- AGEN $18.74
- SFWL $1.60
- Technical
- Relative Strength Index (RSI)
- AGEN 49.92
- SFWL 59.86
- Support Level
- AGEN $4.71
- SFWL $0.91
- Resistance Level
- AGEN $5.22
- SFWL $1.02
- Average True Range (ATR)
- AGEN 0.36
- SFWL 0.04
- MACD
- AGEN -0.12
- SFWL 0.00
- Stochastic Oscillator
- AGEN 14.76
- SFWL 100.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.